Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Basic Science Track

Nephro- and hepatotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617

Anja Becker, Elisabeth Eppard, Stefan Kuerpig, Christian Fisang, Anna Yordanova, Markus Essler and Hojjat Ahmadzadehfar
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1430;
Anja Becker
3Nuclear Medicine University Hospital Bonn Bonn Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth Eppard
1University Hospital Bonn Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Kuerpig
3Nuclear Medicine University Hospital Bonn Bonn Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Fisang
3Nuclear Medicine University Hospital Bonn Bonn Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Yordanova
2University Hospital Bonn Bonn Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Essler
3Nuclear Medicine University Hospital Bonn Bonn Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hojjat Ahmadzadehfar
3Nuclear Medicine University Hospital Bonn Bonn Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1430

Objectives Radioligand therapy (RLT) with 177Lu-PSMA-617 (Lu-PSMA)(prostate-specific membrane antigen) is a novel targeted therapy for metastatic prostate cancer. There is a need for further investigation regarding renal and hepatic side effects due to this therapy. The aim of this study was to investigate the incidence and severity of nephro- and hepatotoxicity in patients who received Lu-PSMA.

Methods One hundred and nine RLT were performed in 2-month intervals in 49 hormone- and/or chemo-refractory patients (median 2 cycles; range: 1-5) with distant metastases and progressive disease (mean age: 70.8 y/o). Median PSA was 334 ng/ml (range: 4.73-5910). Mean creatinine and GFR were: 0.9 mg/dl and 67 ml /min, respectively. Twenty-eight patients had a history of chemotherapy. All patients received renal and liver function tests on the day before RLT and up to at least 2 months after the last cycle. All patients received a Tc-MAG3 scan to rule out any obstructive renal disease.

Results The patients were treated with a median of 6 GBq Lu-PSMA in each cycle. In the MAG3 scan ten patients showed obstructive renal disease, of whom two had a complete obstruction. In four patients it was necessary to place ureteral stents prior to application of Lu-PSMA. Two months after the last cycle, apart from one patient with a grade 1 nephrotoxicity, no patient showed a grade 3 or 4 nephrotoxicity. The majority of patients did not show any hepatotoxicity. No Patient developed any grade 3 or 4 hepatotoxicity.

Conclusions Severe nephro- and hepatotoxicity have not been observed in our patients. Tc-MAG3 renal scintigraphy is of importance for selecting patients who need a ureteral stent prior to RLT to avoid any severe renal injury.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 57, Issue supplement 2
May 1, 2016
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nephro- and hepatotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Nephro- and hepatotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
Anja Becker, Elisabeth Eppard, Stefan Kuerpig, Christian Fisang, Anna Yordanova, Markus Essler, Hojjat Ahmadzadehfar
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1430;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Nephro- and hepatotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
Anja Becker, Elisabeth Eppard, Stefan Kuerpig, Christian Fisang, Anna Yordanova, Markus Essler, Hojjat Ahmadzadehfar
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1430;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Basic Science Track

  • Imaging adult glioma with 68Ga-citrate PET/MR
  • Evaluation of L-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of Cancer
  • Pretargeted radioimmunotherapy with 225Ac-proteus-DOTA hapten.
Show more Oncology, Basic Science Track

MTA I: Radiopharmaceutical Therapy Posters

  • Somatostatin agonist and mTOR inhibitors as potential radioprotectors or radiosensitizers in neuroendocrine tumor cells
  • Factors for successful thyroid remnant ablation with high-dose radioiodine in iodine-replete region
  • Target organ dose range-based, high-activity Zevalin®-inclusive non-myeloablative conditioning for allogeneic stem cell transplantation: a stratified approach
Show more MTA I: Radiopharmaceutical Therapy Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire